Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Clemons

Showing results (251-260 of 267) with videos related to

Pageof 27
Sort By:
Cancer Treatment Reviews|April 4, 2021
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancerJulian Surujballi, Hely Shah, Brian Hutton, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast CancerSharon F McGee, Mark Clemons, Gregory Pond, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22Edward Chow, Amanda Hird, Galina Velikova, et al.
Breast Cancer Research and Treatment|February 5, 2026
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudyAndréanne Leblanc, Ana-Alicia Beltran-Bless, Gregory R Pond, et al.
Cancer|September 7, 2012
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acidCharles S Cleeland, Jean-Jacques Body, Alison Stopeck, et al.
JNCI Cancer Spectrum|August 14, 2025
REaCT-5G: a randomized trial of bone pain with 5-day-filgrastim vs. pegfilgrastim for neutropenia in breast cancerTerry L Ng, Peter Greenstreet, Carol Stober, et al.
Breast (Edinburgh, Scotland)|April 26, 2021
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropeniaMark Clemons, Dean Fergusson, Anil A Joy, et al.
Journal of Medical Internet Research|March 7, 2025
Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation StudySamer El Kababji, Nicholas Mitsakakis, Elizabeth Jonker, et al.
Cancer Research Communications|October 22, 2025
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast CancerAnil Abraham Joy, Nicholas Cheng, Karen A Gelmon, et al.
Breast (Edinburgh, Scotland)|July 9, 2025
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?Ana-Alicia Beltran-Bless, Gregory R Pond, Jane Bayani, et al.
Pageof 27

Showing results (251-260 of 267) with videos related to

Sort By:
Pageof 27
Cancer Treatment Reviews|April 4, 2021
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancerJulian Surujballi, Hely Shah, Brian Hutton, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast CancerSharon F McGee, Mark Clemons, Gregory Pond, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22Edward Chow, Amanda Hird, Galina Velikova, et al.
Breast Cancer Research and Treatment|February 5, 2026
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudyAndréanne Leblanc, Ana-Alicia Beltran-Bless, Gregory R Pond, et al.
Cancer|September 7, 2012
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acidCharles S Cleeland, Jean-Jacques Body, Alison Stopeck, et al.
JNCI Cancer Spectrum|August 14, 2025
REaCT-5G: a randomized trial of bone pain with 5-day-filgrastim vs. pegfilgrastim for neutropenia in breast cancerTerry L Ng, Peter Greenstreet, Carol Stober, et al.
Breast (Edinburgh, Scotland)|April 26, 2021
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropeniaMark Clemons, Dean Fergusson, Anil A Joy, et al.
Journal of Medical Internet Research|March 7, 2025
Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation StudySamer El Kababji, Nicholas Mitsakakis, Elizabeth Jonker, et al.
Cancer Research Communications|October 22, 2025
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast CancerAnil Abraham Joy, Nicholas Cheng, Karen A Gelmon, et al.
Breast (Edinburgh, Scotland)|July 9, 2025
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?Ana-Alicia Beltran-Bless, Gregory R Pond, Jane Bayani, et al.
Pageof 27